89Zr-trastuzumab-PET gauges treatment response in gastric cancer

04/24/2013 | HealthImaging.com

PET imaging with 89Zr-trastuzumab is effective in monitoring treatment response in animals with human epidermal growth factor receptor 2-positive stomach cancer being treated with afatinib, according to findings from a study published in The Journal of Nuclear Medicine. Researchers said 89Zr-trastuzumab-PET performed better than 18F-FDG-PET in determining drug uptake. There is a need for human studies to validate the efficacy of the method in monitoring treatment response, researchers added.

View Full Article in:

HealthImaging.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ
RN Care Manager
MJHS
Brooklyn, NY
Director of Utilization Management
Meridian Health Plan
Chicago, IL
Senior Manager, Healthcare Reform
Avalere Health
Washington, DC